Key points are not available for this paper at this time.
This model is the first immunocompetent mouse model similar to TME of human clinical PM with fibrosis. By using this model, new treatment strategies for PM, such as anti-CAFs therapies, may be developed.
Fujimori et al. (Tue,) studied this question.